Charles D. Hyman’s AbbVie ABBV Stock Holding History

Charles D. Hyman’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	$5.05M	Sell	29,433 -152	-0.5%	-$25.2K	0.28%	58
2024 Q1	$5.39M	Buy	29,585 +766	+3%	+$132K	0.3%	58
2023 Q4	$4.47M	Sell	28,819 -25	-0.1%	-$3.65K	0.27%	62
2023 Q3	$4.3M	Hold	28,844	–	–	0.28%	63
2023 Q2	$3.89M	Sell	28,844 -15,116	-34%	-$2.22M	0.24%	67
2023 Q1	$4.6M	Buy	43,960 +16,073	+58%	+$2.46M	0.31%	58
2022 Q4	$4.51M	Hold	27,887	–	–	0.31%	61
2022 Q3	$3.74M	Buy	27,887 +20	+0.1%	+$2.87K	0.29%	64
2022 Q2	$4.27M	Buy	27,867 +106	+0.4%	+$16.2K	0.31%	62
2022 Q1	$4.5M	Buy	27,761 +1,000	+4%	+$145K	0.28%	62
2021 Q4	$3.62M	Buy	26,761 +2,532	+10%	+$299K	0.23%	73
2021 Q3	$2.61M	Sell	24,229 -659	-3%	-$75.3K	0.18%	84
2021 Q2	$2.8M	Hold	24,888	–	–	0.2%	82
2021 Q1	$2.69M	Hold	24,888	–	–	0.2%	78
2020 Q4	$2.67M	Sell	24,888 -1,624	-6%	-$156K	0.21%	79
2020 Q3	$2.32M	Sell	26,512 -950	-3%	-$89.4K	0.21%	78
2020 Q2	$2.7M	Buy	27,462 +589	+2%	+$51.9K	0.26%	73
2020 Q1	$2.05M	Sell	26,873 -250	-0.9%	-$21.3K	0.26%	69
2019 Q4	$2.4M	Buy	27,123 +313	+1%	+$26K	0.24%	72
2019 Q3	$2.03M	Hold	26,810	–	–	0.21%	74
2019 Q2	$1.95M	Buy	26,810 +675	+3%	+$53.1K	0.2%	75
2019 Q1	$2.11M	Buy	26,135 +5,001	+24%	+$409K	0.22%	78
2018 Q4	$1.95M	Hold	21,134	–	–	0.23%	76
2018 Q3	$2M	Sell	21,134 -1,185	-5%	-$112K	0.21%	80
2018 Q2	$2.07M	Hold	22,319	–	–	0.23%	77
2018 Q1	$2.11M	Hold	22,319	–	–	0.24%	77
2017 Q4	$2.16M	Sell	22,319 -1,650	-7%	-$156K	0.25%	76
2017 Q3	$2.13M	Buy	23,969 +1,200	+5%	+$91.3K	0.26%	73
2017 Q2	$1.65M	Hold	22,769	–	–	0.21%	75
2017 Q1	$1.48M	Hold	22,769	–	–	0.2%	80
2016 Q4	$1.43M	Buy	22,769 +235	+1%	+$14.3K	0.2%	79
2016 Q3	$1.42M	Hold	22,534	–	–	0.21%	80
2016 Q2	$1.4M	Hold	22,534	–	–	0.21%	81
2016 Q1	$1.29M	Sell	22,534 -50	-0.2%	-$2.79K	0.2%	80
2015 Q4	$1.34M	Sell	22,584 -269	-1%	-$15.5K	0.22%	79
2015 Q3	$1.24M	Hold	22,853	–	–	0.22%	79
2015 Q2	$1.53M	Hold	22,853	–	–	0.25%	78
2015 Q1	$1.34M	Hold	22,853	–	–	0.21%	78
2014 Q4	$1.5M	Sell	22,853 -4,435	-16%	-$280K	0.24%	76
2014 Q3	$1.58M	Hold	27,288	–	–	0.26%	72
2014 Q2	$1.54M	Buy	27,288 +194	+0.7%	+$10.2K	0.26%	77
2014 Q1	$1.39M	Hold	27,094	–	–	0.25%	80
2013 Q4	$1.43M	Buy	27,094 +1,375	+5%	+$67.6K	0.26%	77
2013 Q3	$1.15M	Buy	25,719 +800	+3%	+$35.5K	0.23%	83
2013 Q2	$1.03M	Buy	+24,919	New	+$1.09M	0.21%	83

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Charles D. Hyman's ABBV Position: Q2 2024 in Review

Charles D. Hyman reduced its AbbVie (ABBV) stake by 0.51% in Q2 2024, selling an estimated $25.2K and leaving 29,433 shares worth $5.05M. The position accounts for 0.28% of the portfolio, ranked #58.

Charles D. Hyman first reported a position in ABBV in Q2 2013 and has held it in 45 quarters since. The position peaked at $5.39M in Q1 2024. 3,364 funds tracked by Wall St. Rank hold ABBV as of Q2 2024.

Charles D. Hyman held 29,433 shares of AbbVie worth $5.05M as of Q2 2024.
Charles D. Hyman sold 152 AbbVie shares in Q2 2024, an estimated $25.2K.
AbbVie made up 0.28% of Charles D. Hyman's portfolio in Q2 2024, its #58 holding.
Charles D. Hyman first reported a position in AbbVie in Q2 2013 and has held it in 45 quarters since.
Charles D. Hyman's AbbVie position peaked at $5.39M in Q1 2024.
3,364 funds tracked by Wall St. Rank held AbbVie as of Q2 2024.

Based on Charles D. Hyman's 13F filing for Q2 2024, filed 25 Jul 2024.